ClinicalTrials.gg
CompletedNCT00287729Updated Apr 17, 2017Results posted

Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

A Phase 3 interventional study of Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Genentech, Inc.. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-04-17.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Enrollment
7th of 21
344 · median 89
Started
2006
with 1 other
Phase 3
6 of 21
1 open now
Registered
2nd of 21
by date
Lead sponsor
5 of 21
Genentech, Inc.

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 7th largest by enrollment, is one of 2 that started in 2006, is one of 6 in phase 3, and was the 2nd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.

Read the detailed description

This is a Phase 3, randomized, double-blind, placebo-controlled, safety and efficacy study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). Approximately 320 patients at approximately 50 centers will be randomly assigned (1:1) to receive pirfenidone 2403 milligrams or placebo equivalent administered in divided doses three times per day (TID) with food. The primary outcome variable will be the absolute change in percent predicted Forced Vital Capacity from Baseline to Week 72. Patients will be randomized by geographic region.

Patients will receive blinded study treatment from the time of randomization until the last patient randomized has been treated for 72 weeks. A Data Monitoring Committee (DMC) will periodically review safety and efficacy data to ensure patient safety.

After week 72, patients who meet the Progression of Disease (POD) definition, which is a ≥ 10% absolute decrease in percent predicted Forced Vital Capacity or a ≥ 15% absolute decrease in percent predicted carbon monoxide diffusing capacity (DLco), will be eligible to receive permitted idiopathic pulmonary fibrosis therapies in addition to their blinded study drug. Permitted idiopathic pulmonary therapies include corticosteroids, azathioprine, cyclophosphamide and N-acetyl-cysteine (with restrictions).

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Idiopathic
  • Pulmonary
  • Fibrosis
  • Lung
  • Pirfenidone
  • InterMune
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Primary Inclusion criteria:

  • diagnosis of idiopathic pulmonary fibrosis
  • 40 to 80 years of age
  • Forced Vital Capacity ≥ 50% predicted value
  • carbon monoxide diffusing capacity (DLco) ≥ 35% predicted value
  • either Forced Vital Capacity or carbon monoxide diffusing capacity (DLco) ≤ 90% predicted value
  • no improvement in past year
  • able to walk 150 meters in 6 minutes and maintain saturation ≥ 83% while on no more than 6 liters per minute supplemental oxygen

Primary Exclusion criteria:

  • unable to undergo pulmonary function testing
  • evidence of significant obstructive lung disease or airway hyper-responsiveness
  • in the clinical opinion of the investigator, the patient is expected to need and be eligible for a lung transplant within 72 weeks of randomization
  • active infection
  • liver disease
  • cancer or other medical condition likely to result in death within 2 years
  • diabetes
  • pregnancy or lactation
  • substance abuse
  • personal or family history of long syndrome
  • other IPF treatment
  • unable to take study medication
  • withdrawal from other IPF trials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
344 participants (actual)

Study arms

  • Active comparator
    2403 mg/day pirfenidone

    2403 mg/day pirfenidone dose group.

    Drug: Pirfenidone

  • Placebo comparator
    placebo

    Placebo equivalent.

    Drug: Placebo

Interventions

  • 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.

  • DrugPlacebo

    Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.

06

What researchers measure

Primary outcomes

  1. Absolute Change in Percent Predicted Forced Vital Capacity(FVC)

    Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. It is calculated as the simple difference between baseline Percent Predicted FVC measurements and week 72 Percent Predicted FVC measurements.

    Time frame: Baseline to week 72

Secondary outcomes

  1. Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity

    Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (\<10% but \>=0% decline), moderate decline (\<20% but \>=10% decline), severe decline (\>=20% decline), mild improvement (\>0% but \<10% improvement), or moderate improvement (\>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experience Categorical Change in Percent Predicted Forced Vital Capacity.

    Time frame: Baseline to week 72

  2. Progression-free Survival

    Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death.

    Time frame: Baseline to Week 72

  3. Change in the Six-Minute Walk Test (6MWT) Distance

    The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test. This measure was calculated as the simple difference between baseline distanced walked over 6 minutes and week 72 distance walked over 6 minutes as measured in meters (m).

    Time frame: Baseline to Week 72

  4. Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test

    The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level. It is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements.

    Time frame: Baseline to Week 72

  5. Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs

    The change from baseline to week 72 in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs. It is calculated as the simple difference between baseline DLco measurements and week 72 DLco measurements.

    Time frame: Baseline to Week 72

  6. Change in Dyspnea Score

    The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5),with 0= not at all breathless, 4= severely breathless and 5= Maximally or unable to do because of breathlessness.

    Time frame: Baseline to Week 72

  7. Worsening of IPF

    Worsening of IPF was defined by the occurrence of any of the following events: Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization.

    Time frame: Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.

07

Results

Posted Jun 13, 2011

Participant flow

Participant flow — Overall Study
MilestonePirfenidone (2403 mg/d)Placebo
Started171173
Completed137142
Not completed3431

Outcome measures

PrimaryAbsolute Change in Percent Predicted Forced Vital Capacity(FVC)

Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. It is calculated as the simple difference between baseline Percent Predicted FVC measurements and week 72 Percent Predicted FVC measurements.

Time frame:
Baseline to week 72
Reported as:
Mean · Change in Percent Predicted FVC
Absolute Change in Percent Predicted Forced Vital Capacity(FVC)
Change in Percent Predicted FVCPirfenidone (2403 mg/d)Placebo
Absolute Change in Percent Predicted Forced Vital Capacity(FVC)-9 ± 19.58-10 ± 19.12
SecondaryCategorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity

Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (\<10% but \>=0% decline), moderate decline (\<20% but \>=10% decline), severe decline (\>=20% decline), mild improvement (\>0% but \<10% improvement), or moderate improvement (\>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experience Categorical Change in Percent Predicted Forced Vital Capacity.

Time frame:
Baseline to week 72
Reported as:
Number · Patients
Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity
PatientsPirfenidone (2403 mg/d)Placebo
Decline >=20% or death or lung transplantation2023
Decline <20% but >= 10%1923
Decline <10% but > 0%8889
Improvement of >=0% but <10%4133
Improvement of >=10%35
SecondaryProgression-free Survival

Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death.

Time frame:
Baseline to Week 72
Reported as:
Number · Number of Patients with Progression
Progression-free Survival
Number of Patients with ProgressionPirfenidone (2403 mg/d)Placebo
Death or Disease Progression5460
Decline in percent predicted FVC >=10%3141
Decline in percent predicted DLco >=15%109
Death Before Disease Progression1310
SecondaryChange in the Six-Minute Walk Test (6MWT) Distance

The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test. This measure was calculated as the simple difference between baseline distanced walked over 6 minutes and week 72 distance walked over 6 minutes as measured in meters (m).

Time frame:
Baseline to Week 72
Reported as:
Mean · Change in Distance Walked in Meters
Change in the Six-Minute Walk Test (6MWT) Distance
Change in Distance Walked in MetersPirfenidone (2403 mg/d)Placebo
Change in the Six-Minute Walk Test (6MWT) Distance-45 ± 140-77 ± 128
SecondaryChange in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test

The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level. It is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements.

Time frame:
Baseline to Week 72
Reported as:
Mean · Change,Worst Oxygen Saturation (Percent)
Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test
Change,Worst Oxygen Saturation (Percent)Pirfenidone (2403 mg/d)Placebo
Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test-1.9 ± 3.83-1.3 ± 6.63
SecondaryChange in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs

The change from baseline to week 72 in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs. It is calculated as the simple difference between baseline DLco measurements and week 72 DLco measurements.

Time frame:
Baseline to Week 72
Reported as:
Mean · Change in Percent Predicted DLco
Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs
Change in Percent Predicted DLcoPirfenidone (2403 mg/d)Placebo
Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs-9.8 ± 12.61-9.2 ± 13.24
SecondaryChange in Dyspnea Score

The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5),with 0= not at all breathless, 4= severely breathless and 5= Maximally or unable to do because of breathlessness.

Time frame:
Baseline to Week 72
Reported as:
Mean · Change in Dyspnea Score
Change in Dyspnea Score
Change in Dyspnea ScorePirfenidone (2403 mg/d)Placebo
Change in Dyspnea Score11.9 ± 24.7213.9 ± 27.89
SecondaryWorsening of IPF

Worsening of IPF was defined by the occurrence of any of the following events: Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization.

Time frame:
Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.
Reported as:
Number · Number of Patients Who Worsened
Worsening of IPF
Number of Patients Who WorsenedPirfenidone (2403 mg/d)Placebo
Woresening IPF2432
Acute IPF exacerbation21
IPF-related death36
Lung transplantation22
Respiratory hospitalization1723
Patients Censored146141

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirfenidone (2403 mg/d)—53/171 (31%)169/171 (98.8%)
Placebo—51/173 (29.5%)170/173 (98.3%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventPirfenidone (2403 mg/d)Placebo
Idiopathic Pulmonary FibrosisRespiratory, thoracic and mediastinal disorders13/17117/173
Lobar PneumoniaInfections and infestations7/1717/173
Coronary Artery DiseaseCardiac disorders6/1710/173
Respiratory FailureRespiratory, thoracic and mediastinal disorders4/1716/173
BronchitisInfections and infestations0/1715/173
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders2/1713/173
Atrial FibrillationCardiac disorders2/1711/173
Sick Sinus SyndromeCardiac disorders2/1710/173
ColitisGastrointestinal disorders2/1710/173
FallInjury, poisoning and procedural complications2/1711/173
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPirfenidone (2403 mg/d)Placebo
RashSkin and subcutaneous tissue disorders58/17122/173
CoughRespiratory, thoracic and mediastinal disorders51/17154/173
Idiopathic Pulmonary FibrosisRespiratory, thoracic and mediastinal disorders31/17140/173
DyspnoeaRespiratory, thoracic and mediastinal disorders28/17134/173
DizzinessNervous system disorders30/17118/173
HeadacheNervous system disorders28/17125/173
Back PainMusculoskeletal and connective tissue disorders21/17115/173
AnorexiaMetabolism and nutrition disorders18/1716/173
Photosensitivity reactionSkin and subcutaneous tissue disorders17/1714/173
ArthralgiaMusculoskeletal and connective tissue disorders16/17111/173

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pirfenidone (2403 mg/d)PlaceboTotal
<=18 years000
Between 18 and 65 years7061131
>=65 years101112213
Age, Continuous
Age, Continuous(years)Pirfenidone (2403 mg/d)PlaceboTotal
Mean66.8 ± 7.9067.0 ± 7.8066.9 ± 7.84
Sex: Female, Male
Sex: Female, Male(Participants)Pirfenidone (2403 mg/d)PlaceboTotal
Female484997
Male123124247
Region of Enrollment
Region of Enrollment(participants)Pirfenidone (2403 mg/d)PlaceboTotal
United States148150298
Europe232245
Australia011
08

Study locations

1 site
  • InterMune, Inc.
    Brisbane, California 94005, United States
09

References and documents

Publications

  • Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, Schwartz DA, Maher TM, Flores C, Noth I, Yaspan BL, Jenkins RG, Wain LV; International IPF Genetics Consortium. Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax. 2022 Aug;77(8):829-833. doi: 10.1136/thoraxjnl-2021-218577. Epub 2022 Jun 10. PubMed 35688625 ↗
  • Kreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, Atwood M, Kirchgaessler KU, Maher TM. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Jul 1;204(1):74-81. doi: 10.1164/rccm.202003-0669OC. PubMed 33434107 ↗
  • Glassberg MK, Nathan SD, Lin CY, Morgenthien EA, Stauffer JL, Chou W, Noble PW. Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Adv Ther. 2019 Oct;36(10):2910-2926. doi: 10.1007/s12325-019-01052-y. Epub 2019 Aug 10. Erratum In: Adv Ther. 2019 Oct;36(10):2927-2929. doi: 10.1007/s12325-019-01082-6. PubMed 31401786 ↗
  • Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler KU, Stauffer JL, Morgenthien E, Chou W, Limb SL, Noble PW. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019 Jul;153:44-51. doi: 10.1016/j.rmed.2019.04.016. Epub 2019 Apr 24. PubMed 31153107 ↗
  • Kreuter M, Lederer DJ, Molina-Molina M, Noth I, Valenzuela C, Frankenstein L, Weycker D, Atwood M, Kirchgaessler KU, Cottin V. Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. Chest. 2019 Oct;156(4):706-714. doi: 10.1016/j.chest.2019.04.015. Epub 2019 Apr 29. PubMed 31047956 ↗
  • Nathan SD, Costabel U, Glaspole I, Glassberg MK, Lancaster LH, Lederer DJ, Pereira CA, Trzaskoma B, Morgenthien EA, Limb SL, Wells AU. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2019 Apr;155(4):712-719. doi: 10.1016/j.chest.2018.11.008. Epub 2018 Nov 22. PubMed 30472023 ↗
  • Nathan SD, Lancaster LH, Albera C, Glassberg MK, Swigris JJ, Gilberg F, Kirchgaessler KU, Limb SL, Petzinger U, Noble PW. Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. BMJ Open Respir Res. 2018 Aug 2;5(1):e000323. doi: 10.1136/bmjresp-2018-000323. eCollection 2018. PubMed 30116539 ↗
  • Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respir Med. 2018 Aug;6(8):615-626. doi: 10.1016/S2213-2600(18)30185-1. Epub 2018 Jun 29. PubMed 30072107 ↗
  • Paterniti MO, Bi Y, Rekic D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC. PubMed 28388260 ↗
  • Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax. 2017 Feb;72(2):148-153. doi: 10.1136/thoraxjnl-2016-208819. Epub 2016 Oct 5. PubMed 27708114 ↗
  • Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11. PubMed 26968970 ↗
  • Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016. PubMed 26835133 ↗
  • Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13. PubMed 21571362 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years 7 months after primary completion. A results delay was requested in Aug 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2006
First posted
Feb 7, 2006
Start
Apr 2006
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results delay requested
Aug 25, 2009
Results first posted
Jun 13, 2011
Last update
Apr 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00287729
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Feb 7, 2006
Start date
Apr 2006
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Jun 13, 2011
Last update
Apr 17, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion